General AML

ASCO 2019 | Impact of genetic mutations in gilteritinib treated patients with FLT-3 mutated R/R AML

L:

At the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, Mark J. Levis, Johns Hopkins University, Baltimore, US discussed an abstract based on the impact of co-mutations and FLT-3 allelic burden on the outcome of patients treated with gilteritinib in the randomized ADMIRAL study (NCT02421939). Dr. Levis explained that in this follow-up study, the FLT3 inhibitor, gilteritinib, showed superior response and overall survival (OS) compared with salvage chemotherapy (SC) in patients with FLT3mut+ R/R AML. Dr. Levis analyzed the impact of baseline co-mutations and FLT3-ITD allelic ratio (AR) on response and OS.